Literature DB >> 18326821

CD38 expression in chronic lymphocytic leukemia is regulated by the tumor microenvironment.

Piers E M Patten1, Andrea G S Buggins, Julie Richards, Andrew Wotherspoon, Jon Salisbury, Ghulam J Mufti, Terry J Hamblin, Stephen Devereux.   

Abstract

Chronic lymphocytic leukemia (CLL) is a lymphoproliferative disease with a highly variable outcome. The prognosis of patients with CLL may be predicted using a number of biomarkers, including the level of CD38 expression at the leukemic cell surface. This study investigates the hypothesis that CD38 expression by CLL cells reflects interactions with nonmalignant cells within pseudofollicles in secondary lymphoid tissue where tumor cell proliferation is thought to occur. CD38 expression is higher in tissues that contain pseudofollicles compared with those that do not. In addition, we show that CD38 expression in CLL is dynamic, changes in response to contact with activated CD4(+) T cells, and identifies cells that are primed to proliferate. Finally, we demonstrate close contact between activated CD4(+) T cells and proliferating tumor in primary patient tissue. Proliferating tumor cells in lymph nodes express CD38, which is in turn associated with an increased number of CD31(+) vascular endothelial cells. Although the factors resulting in colocalization of tumor, T cells, and endothelium remain unclear, the existence of these cellular clusters may provide an explanation for the association between CD38 expression and adverse outcome in CLL and suggests novel therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18326821     DOI: 10.1182/blood-2007-08-108605

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  80 in total

1.  Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

Authors:  David Oscier; Rachel Wade; Zadie Davis; Alison Morilla; Giles Best; Sue Richards; Monica Else; Estella Matutes; Daniel Catovsky
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

2.  Spleen tyrosine kinase inhibitors reduce CD40L-induced proliferation of chronic lymphocytic leukemia cells but not normal B cells.

Authors:  Anna Parente-Ribes; Sigrid S Skånland; Simone Bürgler; Audun Os; Dong Wang; Bjarne Bogen; Geir E Tjønnfjord; Kjetil Taskén; Ludvig A Munthe
Journal:  Haematologica       Date:  2015-11-20       Impact factor: 9.941

3.  Stromal endothelial cells establish a bidirectional crosstalk with chronic lymphocytic leukemia cells through the TNF-related factors BAFF, APRIL, and CD40L.

Authors:  Montserrat Cols; Carolina M Barra; Bing He; Irene Puga; Weifeng Xu; April Chiu; Wayne Tam; Daniel M Knowles; Stacey R Dillon; John P Leonard; Richard R Furman; Kang Chen; Andrea Cerutti
Journal:  J Immunol       Date:  2012-05-16       Impact factor: 5.422

Review 4.  Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Authors:  Lisa Pleyer; Alexander Egle; Tanja Nicole Hartmann; Richard Greil
Journal:  Nat Rev Clin Oncol       Date:  2009-06-02       Impact factor: 66.675

5.  High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation.

Authors:  Jan A Burger; Maite P Quiroga; Elena Hartmann; Andrea Bürkle; William G Wierda; Michael J Keating; Andreas Rosenwald
Journal:  Blood       Date:  2008-12-12       Impact factor: 22.113

Review 6.  B cell receptor signaling in chronic lymphocytic leukemia.

Authors:  Jan A Burger; Nicholas Chiorazzi
Journal:  Trends Immunol       Date:  2013-08-05       Impact factor: 16.687

Review 7.  Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.

Authors:  Ting-Ting Han; Lei Fan; Jian-Yong Li; Wei Xu
Journal:  Cancer Biol Ther       Date:  2013-10-22       Impact factor: 4.742

Review 8.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

9.  CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells.

Authors:  Silvia Deaglio; Semra Aydin; Maurizia Mello Grand; Tiziana Vaisitti; Luciana Bergui; Giovanni D'Arena; Giovanna Chiorino; Fabio Malavasi
Journal:  Mol Med       Date:  2009-11-20       Impact factor: 6.354

10.  Targeting chronic lymphocytic leukemia cells with a humanized monoclonal antibody specific for CD44.

Authors:  Suping Zhang; Christina C N Wu; Jessie-F Fecteau; Bing Cui; Liguang Chen; Ling Zhang; Rongrong Wu; Laura Rassenti; Fitzgerald Lao; Stefan Weigand; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.